Literature DB >> 9816018

Dose intensity in advanced ovarian cancer: have we answered the question?

D Fennelly1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 9816018

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


× No keyword cloud information.
  6 in total

1.  Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide.

Authors:  S S Dharap; Y Wang; P Chandna; J J Khandare; B Qiu; S Gunaseelan; P J Sinko; S Stein; A Farmanfarmaian; T Minko
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-25       Impact factor: 11.205

2.  pHLIP-mediated translocation of membrane-impermeable molecules into cells.

Authors:  Damien Thévenin; Ming An; Donald M Engelman
Journal:  Chem Biol       Date:  2009-07-31

3.  Use of biotin targeted methotrexate-human serum albumin conjugated nanoparticles to enhance methotrexate antitumor efficacy.

Authors:  Azade Taheri; Rassoul Dinarvand; Faranak Salman Nouri; Mohammad Reza Khorramizadeh; Atefeh Taheri Borougeni; Pooria Mansoori; Fatemeh Atyabi
Journal:  Int J Nanomedicine       Date:  2011-09-08

4.  IL-6 production in ovarian carcinoma is associated with histiotype and biological characteristics of the tumour and influences local immunity.

Authors:  I Kryczek; M Gryboś; L Karabon; A Klimczak; A Lange
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

5.  Chemopreventive effects of Peucedanum praeruptorum DUNN and its major constituents on SGC7901 gastric cancer cells.

Authors:  Taigang Liang; Wenyan Yue; Qingshan Li
Journal:  Molecules       Date:  2010-11-09       Impact factor: 4.411

6.  Canine parvovirus-like particles, a novel nanomaterial for tumor targeting.

Authors:  Pratik Singh; Giuseppe Destito; Anette Schneemann; Marianne Manchester
Journal:  J Nanobiotechnology       Date:  2006-02-13       Impact factor: 10.435
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.